Drug modification of digital vascular reactivity to vasoactive substances.
D000450:Aldosterone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D001581:Benzothiadiazines / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D005385:Fingers / Q000098:blood supply*; D006145:Guanethidine / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology; D009638:Norepinephrine / Q000494:pharmacology; D011241:Prednisone / Q000494:pharmacology; D011928:Raynaud Disease / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D012965:Sodium Chloride / Q000494:pharmacology; D013148:Spironolactone / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D001581:Benzothiadiazines; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D013148:Spironolactone; D012965:Sodium Chloride; D000450:Aldosterone; D004295:Dihydroxyphenylalanine; D011241:Prednisone; D009638:Norepinephrine; D014439:Tyramine; D006145:Guanethidine